OTCMKTS:ULGX - Urologix Stock Price, Price Target & More

$0.0040 +0.00 (+60.00 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$0.0025
Today's Range$0.0040 - $0.0040
52-Week Range$0.0009 - $0.0078
Volume100 shs
Average Volume347,411 shs
Market Capitalization$50,000.00
P/E RatioN/A
Dividend YieldN/A
Beta7.26

About Urologix (OTCMKTS:ULGX)

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.

Receive ULGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ULGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ULGX
CUSIPN/A
Phone612-475-1400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares21,820,000

How to Become a New Pot Stock Millionaire

Urologix (OTCMKTS:ULGX) Frequently Asked Questions

What is Urologix's stock symbol?

Urologix trades on the OTCMKTS under the ticker symbol "ULGX."

How were Urologix's earnings last quarter?

Urologix (OTCMKTS:ULGX) released its quarterly earnings results on Thursday, February, 5th. The company reported ($0.02) EPS for the quarter. The business earned $3.10 million during the quarter, compared to the consensus estimate of $3.80 million. View Urologix's Earnings History.

Who are some of Urologix's key competitors?

Who are Urologix's key executives?

Urologix's management team includes the folowing people:
  • Bryon Merade, Chairman and Chief Exec. Officer
  • Mr. Ash Keswani, Pres

Has Urologix been receiving favorable news coverage?

Press coverage about ULGX stock has trended somewhat negative on Monday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Urologix earned a media sentiment score of -0.06 on Accern's scale. They also assigned news stories about the company an impact score of 44.77 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Urologix?

Shares of ULGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Urologix's stock price today?

One share of ULGX stock can currently be purchased for approximately $0.0040.

How big of a company is Urologix?

Urologix has a market capitalization of $50,000.00.

How can I contact Urologix?

Urologix's mailing address is 14405 21ST AVE N, MINNEAPOLIS MN, 55447. The company can be reached via phone at 612-475-1400 or via email at [email protected]


MarketBeat Community Rating for Urologix (ULGX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  43
MarketBeat's community ratings are surveys of what our community members think about Urologix and other stocks. Vote "Outperform" if you believe ULGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ULGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Urologix (OTCMKTS:ULGX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/23/2016 forward)

Earnings

Urologix (OTCMKTS:ULGX) Earnings History and Estimates Chart

Earnings by Quarter for Urologix (OTCMKTS:ULGX)

Urologix (OTCMKTS ULGX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/12/2015Q3 2015($0.02)$2.80 millionViewN/AView Earnings Details
2/5/2015Q215($0.02)$3.80 million$3.10 millionViewListenView Earnings Details
11/4/2014Q1 2015($0.02)$3.02 millionViewN/AView Earnings Details
8/19/2014Q4 14($0.17)$3.29 millionViewN/AView Earnings Details
5/6/2014Q3 2014($0.08)$3.36 millionViewN/AView Earnings Details
2/4/2014Q4($0.05)$3.81 millionViewListenView Earnings Details
10/29/2013Q1 2014($0.06)$3.78 millionViewN/AView Earnings Details
8/20/2013Q4 2013($0.05)$4.18 millionViewN/AView Earnings Details
5/1/2013Q3 2013($0.06)($0.06)$3.85 million$4.08 millionViewN/AView Earnings Details
2/5/2013Q2 2013($0.05)($0.06)ViewN/AView Earnings Details
11/14/2012Q113($0.06)($0.05)$4.48 million$4.00 millionViewN/AView Earnings Details
8/23/2012Q4 2012($0.06)($0.08)ViewN/AView Earnings Details
4/26/2012Q3 2012($0.06)ViewN/AView Earnings Details
1/24/2012Q2 2012($0.07)ViewN/AView Earnings Details
11/7/2011Q1 2012($0.09)ViewN/AView Earnings Details
8/23/2011Q4 2011($0.09)ViewN/AView Earnings Details
4/26/2011Q3 2011($0.06)($0.07)ViewN/AView Earnings Details
1/25/2011Q2 2011($0.05)($0.05)ViewN/AView Earnings Details
11/3/2010Q1 2011($0.08)($0.05)ViewN/AView Earnings Details
8/24/2010Q4 2010($0.03)($0.04)ViewN/AView Earnings Details
4/27/2010Q3 2010($0.02)($0.04)ViewN/AView Earnings Details
1/21/2010Q2 2010($0.05)($0.02)ViewN/AView Earnings Details
10/27/2009Q1 2010($0.10)($0.05)ViewN/AView Earnings Details
8/25/2009Q4 2009($0.06)ViewN/AView Earnings Details
4/23/2009Q3 2009($0.07)($0.08)ViewN/AView Earnings Details
1/28/2009Q2 2009($0.07)($0.07)ViewN/AView Earnings Details
11/5/2008Q1 2009($0.09)ViewN/AView Earnings Details
8/28/2008Q4 2008($0.16)ViewN/AView Earnings Details
4/24/2008Q3 2008($0.15)ViewN/AView Earnings Details
1/30/2008Q2 2008($0.24)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Urologix (OTCMKTS:ULGX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Urologix (OTCMKTS ULGX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.50%
Institutional Ownership Percentage: 0.28%
Insider Trading History for Urologix (OTCMKTS:ULGX)

Urologix (OTCMKTS ULGX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/26/2013Gregory FluetCEOBuy17,500$0.31$5,425.00View SEC Filing  
7/12/2013Mitchell DannDirectorBuy20,000$0.30$6,000.00View SEC Filing  
7/10/2013Gregory FluetCEOBuy25,000$0.24$6,000.00View SEC Filing  
7/9/2013Lisa A AckermannEVPBuy18,500$0.24$4,440.00View SEC Filing  
7/8/2013Gregory FluetCEOBuy66,400$0.19$12,616.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Urologix (OTCMKTS ULGX) News Headlines

Source:

SEC Filings

Urologix (OTCMKTS:ULGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Urologix (OTCMKTS:ULGX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Urologix (OTCMKTS ULGX) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.